Sobi
@synagis.com
Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. Learn more about us here.
Sobi's Company Logos
Sobi's Brand Colors
Hex Code
Color name
RGB
HSL
CMYK
#A4A7AA
Gray Chateau
164, 167, 170
210, 3, 65
4, 2, 0, 33
#FFFFFF
White
255, 255, 255
0, 0, 100
0, 0, 0, 0
#265053
Plantation
38, 80, 83
184, 37, 24
54, 4, 0, 67
About Sobi
Discover SYNAGIS, a vital therapy designed to safeguard children at high risk from serious lung disease caused by respiratory syncytial virus (RSV). SYNAGIS (palivizumab) offers protection throughout the 2023-2024 RSV season. This prescription medication, available in 50mg and 100mg injections, is crucial for children born prematurely, those with chronic lung conditions like bronchopulmonary dysplasia (BPD), and infants with specific heart diseases.
SYNAGIS features man-made antibodies to combat RSV effectively, aiming to prevent the disease rather than treating its symptoms. Safety is paramount, as children with severe allergic reactions to SYNAGIS should avoid it. Possible side effects, including fever and rash, are managed under medical supervision.
For further support or information about SYNAGIS, contact SYNAGIS CONNECT at (866)-285-8419. Secure your precious child's health with SYNAGIS – protecting against severe RSV disease is key
Brand industry
Health
Company type
Suggest company type
Year founded
Suggest founded year
Company size
Suggest company size
